Didier Cupissol

Institut de Recherche en Cancérologie de Montpellier — France

Medicine · Health Sciences

46h-index13.9kcitations254works3.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(88), Head and Neck Cancer Studies(50), Cancer Diagnosis and Treatment(26), Hematological disorders and diagnostics(26), Vascular Tumors and Angiosarcomas(24)

Publications254 total

Impact of facial nerve resection in parotid cancer abutting the facial nerve without preoperative paralysis: A multicentric propensity score-based analysis
European Journal of Surgical Oncology·2024Open Access
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial
The Lancet Healthy Longevity·2024· 8 citedOpen Access
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial
The Lancet Healthy Longevity·2024· 10 citedOpen Access
Référentiel national de traitement des carcinomes épidermoïdes des voies aérodigestives supérieures – Principes généraux de traitement
Bulletin du Cancer·2024· 1 cited
Référentiel national de traitement des carcinomes épidermoïdes des voies aérodigestives supérieures
Bulletin du Cancer·2024
NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08)
BMJ Oncology·2023· 9 citedOpen Access
Supplementary Figure from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
2023Open Access
Supplementary Table from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
2023Open Access
Supplementary Table from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
2023Open Access
Supplementary Table from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
2023Open Access
Supplementary Table from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
2023Open Access
Supplementary Figure from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
2023Open Access
Supplementary Table from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
2023Open Access
Supplementary Table from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
2023Open Access
Supplementary Table from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
2023Open Access
Supplementary Table from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
2023Open Access
Supplementary Table from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
2023Open Access
Supplementary Table from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
2023· 1 citedOpen Access
Supplementary Table from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
2023Open Access
Supplementary Table from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
2023Open Access
page 1 of 13Next →

Frequent Co-authors

Jean‐Yves Blay(20), Christine Chevreau(18), Emmanuelle Bompas(17), Nicolas Penel(16), Florence Duffaud(14), François Bertucci(14), Nicolás Isambert(13), María Rios(12), Sophie Piperno‐Neumann(11), Isabelle Ray‐Coquard(10), Jérôme Fayette(10), Antoîne Italiano(10), Cécile Guillemet(9), Corinne Delcambre(8), Esma Saâda-Bouzid(8), Axel Le Cesne(7), J. Guigay(7), Olivier Collard(7), Sylvie Chabaud(6), David Pérol(6)